

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

Examiner Initials *	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)	MM-DD-YYYY		
	AA	US-5,593,972	01-14-1997	David B. Weiner et al.	
	AB	US-5,739,118	04-14-1998	Richard A. Carrano et al.	
	AC	US-5,817,637	10-06-1998	David B. Weiner et al.	
	AD	US-5,830,876	11-03-1998	David B. Weiner et al.	
	AE	US-5,962,428	10-05-1999	Richard A. Carrano et al.	
	AF	US-5,981,505	11-09-1999	David B. Weiner et al.	
	AG	US-5,580,859	12-03-1996	Philip L. Felgner et al.	
	AH	US-5,703,055	12-30-1997	Philip L. Felgner et al.	
	AI	US-5,676,594	10-14-1997	Egbertus M. Joosten et al.	
	AJ	US-4,945,050	07-31-1990	John C. Sanford et al.	
	AK	US-5,036,006	07-30-1997	John C. Sanford et al.	
	AL	US-5,593,972	01-14-1997	David B. Weiner et al.	
	AM	US-5,840,530	11-24-2998	Ulrich A. Gubler et al.	
	AN	US-4,722,848	02-02-1998	Enzo Paoletti et al.	
	AO	US-5,017,487	05-21-1991	Hendrik G. Stunnenberg et al.	
	AP	US-5,077,044	12-31-1991	Bruce Arnold D. Stocker et al.	
	AQ	US-5,110,587	05-05-1992	Enzo Paoletti et al.	
	AR	US-5,112,749	05-12-1992	Robert N. Brey et al.	
	AS	US-5,174,993	12-29-1992	Enzo Paoletti et al.	
	AT	US-5,223,424	06-29-1993	Mark D. Cochran et al.	

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Applicant's unique citation designator number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application packet to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet	2	of	24
-------	---	----	----

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	KO	WO 02/29088 A2		04-11-2002	David Weiner et al.		
	KP	WO 01/24818 A		04-12-2001	D.G.J. Rea		
	KQ	WO 01/85920 A		11-15-2001	Jacques F. Banchereau et al.		
Examiner Signature				Date Considered			

* Applicant's unique citation designator number (optional). * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application packet to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	Agostini, C., et al. "CD8 T-Cell Infiltration in Extravascular Tissues of Patients with Human Immunodeficiency Virus Infection. Interleukin 15 Upmodulates Co-Stimulatory Pathways Involved in the Antigen Presenting Cells of T-cell Interaction." <i>Blood</i> , (1999) 93: 1277-1286.	
	BM	Anderson, S., et al. "Nef from primary isolates of human immunodeficiency virus type 1 suppressed surface CD4 expression in human and mouse T cells" <i>J Virol</i> (1993) 67 : 4923-4931.	
	BN	Anderson D.M. et al., "Chromosomal assignment and genomic structure of IL15," <i>Genomics</i> (1995), 25(3):701-6.	
	BO	Another et al., "Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia," <i>Blood</i> (2002) p. 722-723.	
	BP	Arai, et al., "Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression," <i>J. Immunol.</i> (1989), 142:274-282.	
	BQ	Armitage R.J. et al., "IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation," <i>J. Immunol</i> (1995) Jan 15;154(2):483-90.	
	BR	Ayyavoo, V., et al., "HIV-1 vpr suppresses immune activation and apoptosis through regulation of nuclear factor KB," <i>Nature Medicine</i> , (1997) 3: 1117-1122.	
	BS	Azuma, et al., "Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue," <i>Nucl. Acids Res.</i> (1986), 14:9149-9158.	
	BT	Bamford R.N. et al., "The neuromuscular blocking activity of some monoquaternary androstane derivatives," <i>J Pharm Pharmacol</i> (1971), 23(8):595-9.	
	BU	Borrow, R., et al 1998, "Cytotoxic lymphocyte escape viral variant how important are they in viral evasions of immune clearance in vivo," <i>Immunology Rev.</i> (1998) 164: 37- 51.	
	BV	Bourgeois, C., et al. "A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory," 2002, <i>Science</i> 297: 2060-2063.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BW	Campbell, et al., "Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5)," <i>Proc. Natl. Acad. Sci. USA</i> (1987), 84:6629-6633.	
	BX	Campbell, et al., "Isolation, structure and expression of cDNA and genomic clones for murine eosinophil differentiation factor. Comparison with other eosinophilopoietic lymphokines and identity with interleukin-5," <i>Eur. J. Biochem.</i> (1988), 174:345-352.	
	BY	Cao, H., et al., "Cytotoxic T Lymphocyte Cross- Reactivity among Different HIV-1 Type 1 Clades: Implication for Vaccine Development," <i>J Virol</i> ; (1997) 71: 86158623.	
	BZ	Chang, KH, et al., "Spontaneous Programmed Cell Death of Peripheral Blood Mononuclear Cells from HIV-Infected Persons is Decreased with IL-15," <i>Yonsei Medical Journal</i> , (2000) 41: 112-118.	
	CA	Chiu, et al., "The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes," <i>Cel</i> (1988) 54:541-552.	
	CB	Chaudhary, V.K. et al., "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Nat. Acad. Sci. USA</i> (1990) 87:1066-1070.	
	CC	Devos, et al., "Molecular cloning of human interleukin 2 cDNA and its expression in <i>E. coli</i> ," <i>Nucl. Acids Res.</i> (1983) 11:4307-4323.	
	CD	Finzi, D., et al., "Identification of a Reservoir for HIV-1 Patients on Highly Active Antiviral Therapy," <i>Science</i> , (1997) 278: 1295-1300.	
	CE	Franklin et al. "Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-jun transcriptional activity in U937 human leukemic cells," <i>Oncogene</i> . (1995) Dec 7;11(11):2365-74.	
	CF	Furutani, et al., "Complete nucleotide sequence of the gene for human interleukin 1 alpha," <i>Nucl. Acids Res.</i> (1985) 14:3167-3179.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133711.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CI	Fuse, et al., "Organization and structure of the mouse interleukin-2 gene," <i>Nucl. Acids Res.</i> (1984), 12:9323-9331	
	CJ	Gilmore et al., "The I kappa B proteins: members of a multifunctional family," <i>Trends Genet</i> 1993 Dec;9(12):427-33	
	CK	Giri J.G. et al., "Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15," <i>Embo J</i> (1994), 13(12):2822-30.	
	CL	Giri et al., "Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor," <i>EMBO J</i> , 1995 Aug 1;14(15):3654-63.	
	CM	Goulder PJ, et al "Late escape from an immunodominant cytotoxic T lymphocyte response associated with progression to AIDS," <i>Nature Medicine</i> , (1997) 3 : 212-217.	
	CN	Goulder PJ, et al "Patterns of immunodominance in HIV-1 specific cytotoxic T lymphocyte response in two human histocompatibility leukocyte antigens HLA identical siblings with HLA A*0201 are influenced by epitope mutations." <i>J Exp Med</i> , (1997) 185: 1423-1433.	
	CO	Grabstein K. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," <i>Science</i> (1994) 264:965.	
	CP	Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> (1984), 312:721-724	
	CQ	Ho, "Therapy of HIV infections: problems and prospects," <i>Bull. New York Acad. Med.</i> (1996) 73,37-45.	
	CR	Holbrook, et al., "T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells," <i>Proc. Natl. Acad. Sci. USA</i> (1984) 81:1634-1638.	
	CS	Howell M.D. et al., "Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis," <i>Proc. Nat. Acad. Sci. USA</i> (1991) 88:10921-10925	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133711.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	Kacani, L., et al. "Role of IL-15 in HIV-1 Associated Hypergammaglobulinemia." <i>Clin Exp Immun</i> (1997) 108: 14-18.	
	CV	Kacani, L., et al. "Interleukin-15 Enhances HIV-1 Driven Polyclonal B-Cell Response in Vitro." <i>Exp and Clin Immun</i> , (1999) 16: 167-179.	
	CW	Kalams, S.A., et al. "The critical need for CD4 help in maintaining effective cytotoxic T Lymphocyte Responses", <i>J. Exp Med.</i> (1998) 188(12): 2199-204	
	CX	Kerkau, T., et al. "The human immunodeficiency virus type 1 (HIV-1) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules," <i>J Exp Med.</i> (1997) 185: 1295-1305.	
	CY	Kim, J., et al, "Modulation of amplitude and direction of in vivo immune responses by co-administration of cassettes with DNA immunogens," <i>Eur. J Immunol.</i> (1998) 28: 1089-1103.	
	CZ	Kim J., et al. "Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo," <i>Journal of Clinical Investigation.</i> (1999) 103: 869-77.	
	DA	Koup, R., et al "Temporal association of cellular immune responses with the initial control of viremia in primary Human immunodeficiency virus type 1 syndrome" <i>Jof Virol</i> , (1994) 68: 4650-4655.	
	DB	Koup, RA, "Virus Escape from CTL recognition," <i>J Exp Med</i> , (1994) 180: 779-782.	
	DC	Kozak et al., "An analysis of vertebrate mRNA sequences: intimations of translational control," <i>J Cell Biol</i> (1991), 115(4):887-903..	
	DD	Ku, CC., et al. "Control of Homeostasis of CD8 Memory T Cells by Opposing Cytokines," <i>Science</i> , (2000) 288: 675- 678.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 24

Complete If Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DE	Lee, et al., "Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities," <i>Proc. Natl. Acad. Sci. USA</i> (1986) 83:2061-2063.	
	DF	Lee et al., "Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements," <i>Cell</i> (1987) 49:741-752	
	DG	Lenburg et al. "VPU induced degradation of CD4: Requirement for specific amino acid residues in the cytoplasmic domain of CD4," <i>J Virol</i> , (1993), 7238-7245.	
	DH	Lin, S.J. et al. "Human Immunodeficiency Virus (HIV) Type-1 GP120-Specific Cell Mediated Cytotoxicity Interleukin-2 (IL-2), IL-12, and IL-15," <i>Clin. Imm. Immunopath.</i> (1997) 82: 163-173	
	DI	Loubeau, M., et al. 1997, "Jo. Enhancement of Natural Killer and Antibody Dependent Cytotoxic Activities of the Peripheral Mononuclear Cells of HIV-Infected Patients by Recombinant IL-15. AIDS" (1997) 16: 137-145	
	DJ	Lucey DR., et al. "In Vitro Immunologic and Virologic Effects of Interleukin-15 on Peripheral Blood Mononuclear Cells from Normal Donors and Human Immunodeficiency Virus Type-1 Infected Patients." <i>Clin Diagn Lab Imm.</i> 4: 43-48.	
	DK	Maeda, et al., "Cloning of interleukin 2 mRNAs from human tonsils," <i>Biochem. Biophys. Res. Comm.</i> (1983), 115:1040-1047.	
	DL	Manjunath, N., et al. "Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes," <i>Journal of Clinical Investigation</i> , (2001) 108: 871-878.	
	DM	March, et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," <i>Nature</i> (1985) 315:641-647	
	DN	Mata, M., et al. "The MHC Class I Restricted Immune Response to HIV-1 gag in Balb/c Mice Selects a Single Epitope That Does not Have a Predictable MHC Binding-Motif and Binds to Kd Through Interactions Between a Glutamine at P5 and Pocket D," <i>Jo of Immun.</i> (1998) 161: 2985-2993.	
	DO	McCarrick III JW, et al. "Positive-negative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells." <i>Transgenic Res</i> (1993) 2: 183-190.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DP	Meyer R., et al., "Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha," <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88(3), 966-970.	
	DQ	Moore AC., et al. "Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice." <i>Journal of Virology</i> . 76 (1): 243-50, 2002 Jan.	
	DR	Murali-Krishna, K., et al. "Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice," <i>Science</i> , (1999) 286 : 1377-1383.	
	DS	Naora H., et al. "Enhanced Survival and Potent Expansion of the Natural Killer Population of HIV Infected Individuals by Exogenous IL-15." <i>Immunology Letters</i> , (1999) 68: 359-367.	
	DT	Noma, et al., "Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter," <i>Nature</i> (1986), 319:640-646.	
	DU	Oksenberg, J.R. et al., "Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients," <i>Nature</i> (1990), 345:344-346.	
	DV	Otsuka, et al., "Structural analysis of the mouse chromosomal gene encoding interleukin 4 which expresses B cell, T cell and mast cell stimulating activities," <i>Nucl. Acids Res.</i> (1987), 15:333-344.	
	DW	Paliard, X et al., "Evidence for the effects of a superantigen in rheumatoid arthritis," <i>Science</i> (1991) 253:325-329.	
	DX	Patki, AH., et al. "Activation of antigen Induced Lymphocyte Proliferation by Interleukin-15 Without the Mitogenic Effect of Interleukin-2 That May Induce Human Immunodeficiency Virus-1 Expression." <i>JCL</i> , (1996) 98: 616-621.	
	DY	Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> (1984), 312:724-729.	
	DZ	Phillips RE, et al. "Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition" <i>Nature</i> , (1991) 354 : 453-459.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **9** of **24**

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	EA	Rauscher et al., "Fos-associated protein p39 is the product of the jun proto-oncogene," <i>Science</i> 1988 240:1010-1016.	
	EB	Rinaldo, C. et al "High Levels of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Memory Cytotoxic T-Lymphocyte Activity and Low Viral Load Are Associated with Lack of Disease in HIV-1 Infected Long-Term Nonprogressors," <i>J Virol.</i> (1995) 69: 5838-5842.	
	EC	Rosenberg, ES, et al. "Vigorous HIV-1 Specific CD4 T cell Responses Associated with Control of Viremia," <i>Science</i> , 278: 1447-1450, (1997).	
	ED	Rosenberg, ES, et al "Immune control of HIV-1 after early treatment of acute infection," <i>Nature</i> , (2000) 407: 523	
	EF	Rowland-Jones S., et al "HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant." <i>Lancet</i> , (1993) 341: 860-86.	
	EG	Rowland-Jones S., et al. "HIV-specific T-cells in HIV- exposed but uninfected Gambian women." <i>Nature Medicine</i> , (1995) 1: 59-64 10.	
	EH	Ruckert et al, "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both," <i>Eur Journal Immunol.</i> (1998), Vol.28; 3312-3320.	
	EJ	Serbina NV., et al. "CD4 (+) T cells are required for the development of cytotoxic CD8 (+) T cells during Mycobacterium tuberculosis infection." <i>Journal of Immunology</i> , (2001) 167: 6991-7000.	
	EK	Shankar P., et al., "Impaired function of circulating HIV-specific CD8 (+) T cells in chronic human immunodeficiency virus infection." <i>Blood</i> , (2000) 96 (9): 3094-101 22.	
	EL	Sin JL, et al. "Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo." <i>Human Gene Therapy</i> , 12: 1091-102, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10

of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EM	Tagaya, Y., "A Pleiotropic Cytokine with Diverse Receptor/Signaling Pathways Whose Expression is Controlled at Multiple Pathways." <i>Immunity</i> (1996) 4: 329-336.	
	EN	Taniguchi, et al., "Structure and expression of a cloned cDNA for human interleukin-2," <i>Nature</i> (1983), 302:305-310.	
	EO	Tanabe, et al., "Molecular cloning and structure of the human interleukin-5 gene," <i>J. Biol. Chem.</i> (1987), 262:16580-16584.	
	EP	Telford, et al., "The murine interleukin 1 beta gene: structure and evolution," <i>Nucl. Acids Res.</i> (1986), 14:9955-9963.	
	EQ	Ushio, et al., "Cloning of the cDNA for human IFN-gamma-inducing factor, expression in <i>Escherichia coli</i> , and studies on the biologic activities of the protein," <i>J. Immunol.</i> (1996), 156:4274-4279.	
	ER	Vieira, et al., "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFL," <i>Proc. Natl. Acad. Sci. USA</i> (1991), 88:1172-1176.	
	ES	Waldmann et al., "The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens," <i>Annu Rev Immunol</i> (1999); 17:19-49.	
	ET	Wierda et al., "CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia," <i>Blood</i> (2000), Vol. 96 pp.2917-2924.	
	EU	Wilkinson P. and Liew F. "Chemoattraction of human blood T lymphocytes by interleukin-15," <i>J Exp Med</i> (1995), 181(3):1255-9.	
	EV	Williams W.V. et al., "Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium," <i>J. Clin Invest.</i> (1992) 90:326-333.	
	EW	Wong, J., et al "Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia," <i>Science</i> , (1997) 278: 1291-1294.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	EX	Wucherpfennig, K.W. et al., "Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein," <i>Science</i> (1990) 248:1016-1019.	
	EY	Yokota, et al., "Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities," <i>Proc. Natl. Acad. Sci. USA</i> (1986), 83:5894-5898.	
	EZ	Yokota, et al., "Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5," <i>Proc. Natl. Acad. Sci. USA</i> (1986), 84:7388-7392.	
	FA	Zhang, X., et al., "Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15," <i>J. Immunol.</i> (1998) 8: 591-599.	
	FB	Borrow, P., et al. "Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes during primary infection demonstrated by rapid selection of CTL escape virus" <i>Nature Medicine</i> , (1997) 3: 205-211.	
	FC	Lu et al, "Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions," <i>J. Virol.</i> (1993) Nov;67(11):6542-50.	
	FD	Accession code Swissprot P01585	
	FE	Accession code Swissprot P01375	
	FF	Accession code D49950	
	FG	Accession code Swissprot U03099	
	FH	Accession code Swissprot P22301	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FI	Accession code Swissprot P05113	
	FJa	Accession code Swissprot P05112	
	FJb	Accession code Swissprot P01583	
	FK	Genbank Accession Number M21121	
	FL	Genbank Accession Number M81104	
	FM	Genbank Accession Number Y00796	
	FN	Genbank Accession Number J03925	
	FO	Genbank Accession Number Y00093	
	FP	Genbank Accession Number M28526	
	FQ	Genbank Accession Number J03132	
	FR	Genbank Accession Number X15606	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FS	Genbank Accession Number X69819	
	FT	Genbank Accession Number Y00636	
	FU	Genbank Accession Number M37435	
	FV	Genbank Accession Number M27087	
	FW	Genbank Accession Number M10663	
	FX	Genbank Accession Number M11220	
	FY	Genbank Accession Number X03655	
	FZ	Genbank Accession Number X03656	
	GA	Genbank Accession Number M37435	
	GB	Genbank Accession Number M13982	
	GC	Genbank Accession Number M23442	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GD	Genbank Accession Number U07414.	
	GE	Genbank Accession Number M67454.	
	GF	Genbank Accession Number M63121.	
	GG	Genbank Accession Number M60275.	
	GH	Genbank Accession Number M32977.	
	GI	Genbank Accession Number J04156.	
	GJ	Genbank Accession Number M57399.	
	GK	Genbank Accession Number U43628.	
	GL	Genbank Accession Number U80016.	
	GM	Genbank Accession Number AF180563 (P40 mRNA)	
	GN	Genbank Accession Number AF180562 (P35 mRNA)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GO	GENBANK Accession number A37867	
	GP	GENBANK Accession number S17233	
	GQ	GENBANK Accession number A42024	
	GR	GENBANK Accession number A57034	
	GS	GENBANK Accession number U34819	
	GT	GENBANK Accession number U34820	
	GU	GENBANK Accession number U34821	
	GV	GENBANK Accession number U34822	
	GW	GENBANK Accession number U35002	
	GX	GENBANK Accession number U35003	
	GY	GENBANK Accession number U35004	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 16 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GZ	GENBANK Accession number U35005	
	HA	GENBANK Accession number L31951	
	HB	GENBANK Accession number M85164	
	HC	GENBANK Accession number M85165	
	HD	GENBANK Accession number Y10256	
	HE	GENBANK Accession number U78798	
	HF	GENBANK Accession number NM001569	
	HG	GENBANK Accession number U70451	
	HH	GENBANK Accession number L19067	
	HI	GENBANK Accession number U66243	
	HJ	GENBANK Accession number M36711	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 17 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	HK	GENBANK Accession number J04111	
	HL	GENBANK Accession number K00650	
	HM	GENBANK Accession number L09753	
	HN	GENBANK Accession number M83554	
	HO	GENBANK Accession number M29039	
	HP	GENBANK Accession number L14542	
	HQ	GENBANK Accession number V01512	
	HR	GENBANK Accession number X54868	
	HS	GENBANK Accession number X54867	
	HT	GENBANK Accession number U65416	
	HU	GENBANK Accession number X92841	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 18 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	HV	GENBANK Accession number TRAIL-R2 AF016849.	
	HW	GENBANK Accession number TRAIL-R3 AF014794.	
	HX	GENBANK Accession number TRAIL-R4 AF021232.	
	HY	GENBANK Accession number U37518.	
	HZ	GENBANK Accession number AF023849.	
	IA	GENBANK Accession number L22473.	
	IB	GENBANK Accession number L07414.	
	IC	GENBANK Accession number Y09908.	
	ID	GENBANK Accession number X91233.	
	IE	GENBANK Accession number X94223.	
	IF	GENBANK Accession number X94222.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 19 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	IG	GENBANK Accession number AF031167	
	IH	GENBANK Accession number U37518	
	II	GenBank Accession No. AF068868 (Sep. 5, 1998).	
	IJ	Genbank Accession Number U13699.	
	IK	Genbank Accession Number U13697.	
	IL	Genbank Accession Number U04343.	
	IM	Genbank Accession number U13698	
	IN	Genbank Accession Number AF018657.	
	IO	Genbank Accession Number AF020501	
	IP	Genbank Accession Number AF022386	
	IQ	Genbank Accession Number AF012535	
	IR	Genbank Accession Number U90875	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 20

of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	IS	Genbank Accession Number M14764	
	IT	Genbank Accession Number U94512	
	IU	Genbank Accession Number U78029	
	IV	Genbank Accession Number U74611	
	IW	Genbank Accession Number U75381	
	IX	Genbank Accession Number Y09392	
	IY	Genbank Accession Number M58286	
	IZ	Genbank Accession Number M67454	
	JA	Genbank Accession Number M67454	
	JB	Genbank Accession Number X63717	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 21 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	JC	Genbank Accession Number X51602	
	JD	Genbank Accession Number X94263	
	JE	Genbank Accession Number M25322	
	JF	Genbank Accession Number X16150	
	JG	Genbank Accession Number S69738	
	JH	Genbank Accession Number M28130	
	JI	Genbank Accession Number M14362	
	JJ	Genbank Accession Number M24736	
	JK	Genbank Accession Number U72395	
	JL	GENBANK Accession number AH006173	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 22 of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	JO	GENBANK Accession number X54869	
	JP	GENBANK Accession number AJ001684	
	JQ	GENBANK Accession number U96846	
	JR	GENBANK Accession number BC021101	
	JS	GENBANK Accession number BC005250	
	JT	GENBANK Accession number BC002878	
	JU	GENBANK Accession number M31126	
	JV	GENBANK Accession number J02893	
	JW	GENBANK Accession number X15102	
	JX	Accession code Swissprot P01374	
	JY	GENBANK Accession number U96845	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 23

of 24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	JZ	GENBANK Accession number AB007839	
	KA	GENBANK Accession number X54870	
	KB	GENBANK Accession number AF461811	
	KC	GENBANK Accession number X79929	
	KD	GENBANK Accession number X75962	
	KE	GENBANK Accession number AF333234	
	KF	GENBANK Accession number AF019047	
	KG	GENBANK Accession number AF018253	
	KH	GENBANK Accession number AF016266	
	KI	GENBANK Accession number U90875.	
	KJ	GENBANK Accession Number U72763	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 24

of

24

Complete if Known

Application Number	10/560,650
Filing Date	05-09-2006
First Named Inventor	David B. Weiner
Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	133171.02001

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	KM	Oru, A. et al. "Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms.", <i>Journal of Immunology</i> , (1997) 158: 255-262.	
	KN	Suzuki, K. et al., "NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.", <i>Journal of Leukocyte Biology</i> , (2001) 69: 531-537.	
	KR	Yang, J-S et al., "Induction of potent Th1-type immune responses from a novel dna vaccine for west Nile virus, " <i>Journal of Infectious Diseases</i> "; (2001) 184:809-816	
	KS	Rueckert, R. et al., "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both.", <i>European Journal of Immunology</i> " (1998) 28: 3312-3320	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.